In fact, molecular targeted therapy against both CD70 and HIF-2α is currently undergoing clinical trials with antibodies against CD70 for renal cell carcinoma, melanoma, lymphomas and other cancers as well as a HIF-2α inhibitor for renal cell carcinoma. Here, EPAS1 is linked to hereditary clear cell renal cell carcinoma.